preladenant   Click here for help

GtoPdb Ligand ID: 5614

Synonyms: SCH-420814 | SCH420814
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Preladenant (SCH 420814) was an adenosine A2A receptor antagonist being developed for Parkinson's disease. Promising Phase 2 trial results did not translate to a significant effect over placebo in Phase 3 trial. Development has been discontinued.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 1
Rotatable bonds 9
Topological polar surface area 125
Molecular weight 503.24
XLogP 2.73
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COCCOc1ccc(cc1)N1CCN(CC1)CCn1ncc2c1nc(N)n1c2nc(n1)c1ccco1
Isomeric SMILES COCCOc1ccc(cc1)N1CCN(CC1)CCn1ncc2c1nc(N)n1c2nc(n1)c1ccco1
InChI InChI=1S/C25H29N9O3/c1-35-15-16-36-19-6-4-18(5-7-19)32-11-8-31(9-12-32)10-13-33-23-20(17-27-33)24-28-22(21-3-2-14-37-21)30-34(24)25(26)29-23/h2-7,14,17H,8-13,15-16H2,1H3,(H2,26,29)
InChI Key DTYWJKSSUANMHD-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Click here to link to ClinicalTrials.gov's list of Phase 3 preladenant trials. More trial details are published in [1-2]
Mechanism Of Action and Pharmacodynamic Effects Click here for help
The anti-Parkinsonian and neuroprotective potential of adenosine A2A receptor antagonists is discussed in [4].